Department of Urology, Sahloul University Hospital, Sousse, Tunisia.
Urology. 2010 Jun;75(6):1392-5. doi: 10.1016/j.urology.2009.06.066. Epub 2009 Sep 25.
To evaluate the effect on the oncological outcomes and recurrences at the prostatic urethra of simultaneous transurethral resection of bladder tumor (TURBT) and benign prostatic hyperplasia (TURP).
The records of 85 men (group 1) who had undergone simultaneous TURBT and TURP at our clinic between 1986 and 2006 and fulfilled the inclusion criteria were retrospectively analyzed and compared with those of 85 men (group 2) who had undergone TURBT only during the same period. Clinicopathologic parameters, recurrence and progression rates, and recurrence rates in the bladder neck and prostatic urethra were determined and compared.
There were no statistically significant differences in clinicopathologic parameters between the 2 groups. At a mean follow-up of 35.2 and 33.1 months in groups 1 and 2, respectively, only 1 patient developed recurrence in prostatic urethra or bladder neck in each group. There were no statistically significant differences between the 2 groups in follow-up time, recurrence, progression or recurrence in the prostatic urethra, and bladder neck.
According to our results, simultaneous transurethral TURP and TURBT can be safely performed without increasing the risk of tumor recurrence in the prostatic urethra.
评估同期经尿道膀胱肿瘤切除术（TURBT）和良性前列腺增生（TURP）治疗对前列腺尿道肿瘤学结果和复发的影响。
回顾性分析了 1986 年至 2006 年间在我院接受同期 TURBT 和 TURP 的 85 例男性（第 1 组）的记录，并将其与同期仅接受 TURBT 的 85 例男性（第 2 组）进行比较。确定并比较了临床病理参数、复发和进展率以及膀胱颈部和前列腺尿道的复发率。
两组患者的临床病理参数无统计学差异。第 1 组和第 2 组的平均随访时间分别为 35.2 个月和 33.1 个月，每组均只有 1 例患者在前列腺尿道或膀胱颈部复发。两组在随访时间、复发、进展或前列腺尿道和膀胱颈部的复发方面无统计学差异。
根据我们的结果，同期经尿道 TURP 和 TURBT 可以安全进行，不会增加前列腺尿道肿瘤复发的风险。
